CLINICAL TRIAL: Quad Therapy Using a Checkpoint Inhibitor with Daratumumab in Relapsed/Refractory Myeloma

Posted: Jul 30, 2016

Later this month (July 2016), Celgene will be opening a Phase 1/2 study for approximately 406 relapsed/refractory myeloma patients using the following drugs to actively treat disease: Dararatumumab dexamethasone Durvalumab Pomalidomide Eligibility criteria includes:

measurable disease as defined by m-protein or serum free light chains
must have failed last line of treatment (refractory to last line of treatment).
must have achieved at least a minimal response to at least one prior anti-myeloma regimen before relapse

If you have received prior treatment with daratumumab or other anti-CD38 therapy, you are not eligible for this trial.

For more information on this clinical trial, click on the SparkCures box below: SparkCures Clinical Trial: Durvalumab & Daratumumab

about the author
Lizzy Smith

Lizzy Smith was diagnosed with myeloma in 2012 at age 44. Within days, she left her job, ended her marriage, moved, and entered treatment. "To the extent I'm able, I want to prove that despite life's biggest challenges, it is possible to survive and come out stronger than ever," she says.